Pain experience in #OA may have different contributing factors Its a while joint disease! What are the future targets in #OA being tested? @RheumNow #ACR23 @Tuhina_Neogi https://t.co/lI06pJrdYR

Wallace et al. Dose, duration, recency dependent relationship between GC and MACE. Even 5mg/day, 30 day use, and use 1 year prior associated with risk. 5mg, 7.5mg, 10mg pred for 90 days - 13%, 19%, 27% MACE increase Abstr#2430 #ACR23 #ACRbest @RheumNow https://t.co/50B5nGqxu9 https://t.co/lNrUbZOm0o

Even low doses of steroids associated with major adverse cardiovascular events! Large VA database - >18k RA pts Dose as low as 5mg/day prednisone for 30 days, 1 year prior to event, associated with increased MACE @RheumNow #ACR23 Abs#2430 https://t.co/JjeoBi7YTD

A#2429 #ACR23 @RheumNow ROMO v DEN - 12 mo RCT 70 GIOP pts at high-risk Mean prednisolone dose 6.6 mg H/o fragility fx in 1/2 pts 12 mo: Increase in spine BMD- ROMO (+7) and DEN (+2) Hip and Femoral neck improved both (1.6% both), not signif diff bw grps AEs: incr injxn site rxn https://t.co/VueuZIjFfM

Physical therapy and lifestyle counseling the main pillars of #OA management are underutilized! Mainstay remains weight loss and exercise! @RheumNow #ACR23 Rrf memorial lecture @Tuhina_Neogi https://t.co/yXqWIEccq4

McCormick et al. No improvement in premature mortality gap in gout over time. 19% increased mortality in gout. Independent of serum urate and CV risk factors. Abstr#2428 #ACR23 @RheumNow https://t.co/lSoEvajN3O https://t.co/uWNokm7LCT

Gout mortality A#2428 #ACR23 @RheumNow 1988-1994 (early) v 2007-2016 (late): Has not improved over time Independent of serum uric acid Female gout: increased mortality Black gout pts also increased Conclusion: the inflammation, not the uric acid is the risk https://t.co/LTFoSFzaBu

The DICKENS study showed no significant improvement in knee pain(p=0.77), WOMAC pain(p=0.64) or function(p=0.68) & stiffness(p=0.34) between diacerin and pbo over 24wks. ⬆️AEs in diacerin grp-diarrhea, colored urine #ACR23 ABSTL05 @RheumNow https://t.co/ht0pGN38il

Super interesting SpA phenotypical type world map. #ACR23 Abs #2195 continues to prove how heterogenous this disease is and the need for additional therapeutic agents for improved patient outcomes. https://t.co/hpKY7usUUb @rheumnow https://t.co/xJ1bx6wOC0

A#2427 #ACR23 @RheumNow PR3+ cell abundance higher in prolif LN, more than membranous. Mostly in tuberulointerstitium Density of PR3+ higher in glomueruli of prolif LN Correlates with activity, not chronicity Urinary PR3 predict renal fxn loss at 3y @jhrheumatology @andreafava https://t.co/vvC8lgZgWO